StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report released on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Up 4.9 %

Minerva Neurosciences stock opened at $2.26 on Tuesday. Minerva Neurosciences has a 52-week low of $2.07 and a 52-week high of $13.49. The firm has a fifty day moving average of $2.46 and a 200-day moving average of $2.77. The firm has a market capitalization of $15.77 million, a P/E ratio of -5.13 and a beta of 0.18.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.